PORTFOLIO NEWS Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor September 19, 2023 Read More » Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress September 11, 2023 Read More » Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics September 7, 2023 Read More » Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746 August 25, 2023 Read More » RAPT Therapeutics Reports Second Quarter 2023 Financial Results August 11, 2023 Read More » ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates August 10, 2023 Read More » Surrozen Provides Second Quarter 2023 Financial Results August 9, 2023 Read More » Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update August 9, 2023 Read More » Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress August 8, 2023 Read More » eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 8, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor September 19, 2023 Read More »
Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress September 11, 2023 Read More »
Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics September 7, 2023 Read More »
Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746 August 25, 2023 Read More »
ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates August 10, 2023 Read More »
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update August 9, 2023 Read More »
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress August 8, 2023 Read More »
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 8, 2023 Read More »
